The transcriptional co-activator TAZ is a potent mediator of alveolar rhabdomyosarcoma tumorigenesis.

CONCLUSIONS: TAZ is oncogenic in aRMS sarcomagenesis. While P3F is currently not therapeutically tractable, targeting TAZ could be a promising novel approach in aRMS.
PMID: 29514840 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - March 7, 2018 Category: Cancer & Oncology Authors: Deel MD, Slemmons KK, Hinson AR, Genadry KC, Burgess BA, Crose LES, Kuprasertkul N, Oristian KM, Bentley RC, Linardic CM Tags: Clin Cancer Res Source Type: research